Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou Connect Reports Positive Data from Autoimmune Drug Trial

publication date: Jan 7, 2016
Suzhou Connect Biopharma reported positive data from a Phase Ib trial of its lead clinical candidate, CBP-307, a novel immune system modulator that Connect is developing as a treatment for autoimmune diseases. The double-blind study showed the drug was well-tolerated and produced a significant reduction in immune activity. CBP-307 is a second generation selective sphingosine-1-phosphate receptor 1 (S1P1) modulator. Connect expects it will show improved safety over first generation S1P1 drugs. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital